Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio

Journal of Clinical Investigation

Volumn 99, Issue 8, 1997, Pages 2005-2019

  Navab, Mohamad ^a   Hama Levy, Susan ^a   Van Lenten, Brian J ^a   Fonarow, Gregg C ^a   Cardinez, Cheryll J ^a   Castellani, Lawrence W ^a   Brennan, Marie Luise ^a,b   Lusis, Aldons J ^a,b   Fogelman, Alan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLESTERASE; CLUSTERIN; LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL INTAKE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIETARY INTAKE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIPID OXIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030898699     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119369     Document Type: Article

References (58)

1. Watson, A.D., M. Navab, S.Y. Hama, A. Sevanian, S.M. Prescott, D.M. Stafforini, T.M. McIntyre, B.N. La Du, A.M. Fogelman, and J.A. Berliner. 1995. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. 95:774-782.
2. Watson, A.D., J.A. Berliner, S.Y. Hama, B.N. La Du, K.F. Faull, A.M. Fogelman, and M. Navab. 1995. Protective effect of high-density lipoprotein associated PON. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96:2882-2891.
3. Van Lenten B.J., S.Y. Hama, F.C. deBeer, D.M. Stafforini, T.M. McIntyre, S.M. Prescott, B.N. La Du, A.M. Fogelman, and M. Navab. 1995. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96:2758-2767.
4. Shih, D.M., L. Gu, S. Hama, Y. Xia, M. Navab, A.M. Fogelman, and A.J. Lusis. 1996. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J. Clin. Invest. 97:1630-1639.
5. Navab, M., S.S. Imes, S.Y. Hama, G.P. Hough, L.A. Ross, R.W. Bork, A.J. Valente, J.A. Berliner, D.C. Drinkwater, H. Laks, and A.M. Fogelman. 1991. Monocyte transmigration induced by modification of low-density lipoprotein in co-cultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis, and is abolished by high density lipoprotein. J. Clin. Invest. 88:2039-2046.
6. Havel, R.J., H.A. Eder, and J.H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins of human serum. J. Clin. Invest. 43:1345-1353.
7. Warden, C.H., J.H. Qiao, L.W. Castellani, and A.J. Lusis. 1993. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science (Wash. DC). 261:469-472.
8. Auerbach, B.J., J.S. Kiely, and J.A. Cornicelli. 1992. A spectrophotometric microtiter-based assay for the detection of hydroperoxy derivatives of linoleic acid. Anal. Biochem. 201(2):375-380.
9. Fogelman, A.M., K. Sykes, B.J. Van Lenten, M.C. Territo, and J.A. Berliner. 1988. Modification of the Recalde method for the isolation of human monocytes. J. Lipid Res. 29:1243-1247.
10. Kelso, G.J., W.D. Stuart, R.J. Richter, C.E. Furlong, T.C. Jordan-Starck, and J.A. Harmony. 1994. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 33:832-839.
11. Griswold, M.D., K. Roberts, and P. Bishop. 1986. Purification and characterization of a sulfated glycoprotein secreted by Sertoli cells. Biochemistry. 25:7265-7270.
12. Gan, K.N., A. Smolen, H.W. Eckerson, and B.N. La Du. 1991. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19:100-106.
13. Cabana, V.G., J.N. Siegel, and S.M. Sabesin. 1989. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J. Lipid Res. 30:39-49.
14. Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage. Nature (Lond.). 227:680-685.
15. Chomczynski, P., and N. Sacchi. 1987. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
16. Doolittle, M.H., R.C. LeBoeuf, C.H. Warden, L.M. Bee, and A.J. Lusis. 1990. A polymorphism affecting apolipoprotein A-II translational efficiency determines high density lipoprotein size and composition. J. Biol. Chem. 265: 16380-16388.
17. Lorenzen, A., and S.W. Kennedy. 1993. A fluorescence based protein assay for use with a microplate reader. Anal. Biochem. 214:346-348.
18. Lowry, O.H., M.J. Rosebrough, A.L. Farr, and R.J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
19. Steinberg, D., S. Parthasarathy, T.E. Carew, J.C. Khoo, and J.L. Witztum. 1989. Beyond cholesterol - Modifications of low density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:915-924.
20. Witztum, J.L., and D. Steinberg. 1991. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88:1785-1792.
21. Parthasarathy, S. 1994. Modified Lipoproteins in the Pathogenesis of Atherosclerosis. R. G. Landes Co., Austin, TX. 91-119.
22. Lusis, A.J., and M. Navab. 1993. Lipoprotein oxidation and gene expression in the artery wall: New opportunities for pharmacologic intervention in atherosclerosis. Biochem. Pharmacol. 46:2119-2126.
23. Gordon, D.J., J.L. Probstfield, R.N. Garrison, J.D. Neaton, W.P. Castelli, J.D. Jacobs Jr., S. Bangdiwala, and H.A. Tyroler. 1989. High density lipoprotein cholesterol and cardiovascular disease. Circulation. 79:8-15.
24. de la Llera Moya, M., V. Atger, J.L. Paul, N. Fournier, N. Moatti, P. Giral, E.K. Friday, and G. Rothblat. 1994. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler. Thromb. 14:1056-1065.
25. Hessler, J.R., A.L. Robertson, Jr., and G.M. Chisolm. 1979. LDL-induced cytotoxicity and endothelial cells in culture. Arteriosclerosis. 32:213-229.
26. Parthasarathy, S. 1994. Mechanism(s) of cell-mediated oxidation of low density lipoprotein. Free Radicals in the Environment, Medicine, and Toxicology. H. Nohl, H. Esterbauer, and C. Rice Evans, editors. Richelieu Press, London. 163-179.
27. Witztum, J.L. 1994. The oxidation hypothesis of atherosclerosis. Lancet. 344:793-795.
28. Chisolm, G.M. 1991. Antioxidants and atherosclerosis: a current assessment. Clin. Cardiol. 14:125-130.
29. Fuster, V., L. Badimon, J.J. Badimon, and J.H. Chesebro. 1992. The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med. 326:242-250, 310-318.
30. Buja, L.M., and J.T. Willerson. 1994. Role of inflammation in coronary plaque disruption. Circulation. 89:503-505.
31. van der Wal, A.C., A.E. Becker, C.M. van der Loos, and P. Das. Site of intimai rupture or erosion of coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:36-44.
32. Galis, Z.S., G.K. Sukhova, M.W. Lark, and P. Libby. 1994. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94:2493-2503.
33. Parthasarathy, S., J. Barnett, and L.G. Fong. 1990. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim. Biophys. Acta. 1044:275-283.
34. 2+-catalyzed oxidation of human low density lipoprotein. FEBS (Fed. Eur. Biochem. Soc.) Lett. 257:435-438.
35. Mackness, M.I., S. Arrol, and P.N. Durrington. 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS (Fed. Eur. Biochem. Soc.) Lett. 286:152-154.
36. Stafforini, D.M., G.A. Zimmerman, T.M. McIntyre, and S.M. Prescott. 1993. The platelet activating factor acetylhydrolase from human plasma prevents oxidative modification of low density lipoprotein. Trans. Assoc. Am. Phys. 105:44-63.
37. La Du, B.N. 1992. Human serum paraoxonase/arylesterase, in Pharmacogenetics of Drug Metabolism. W. Kalow, editor. Pergamon Press, Inc., Tarrytown, NY. 51-91.
38. Abbott, C.A., M.I. Mackness, S. Kumar, A.J. Boulton, and P.N. Durrington. 1995. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 11:1812-1818.
39. Mackness, M.I., and P.N. Durrington. 1995. Paraoxonase: another factor in NIDDM cardiovascular disease. Lancet. 346:856. Letter.
40. Mackness, M.I., S. Arrol, C.A. Abbott, and P.A. Durington. 1993. Protection of low density lipoprotein against oxidative modification by high density lipoprotein paraoxonase. Atherosclerosis. 104:129-135.
41. Mackness, M.I., C.A. Abbott, S. Arrol, and P.A. Durington. 1993. The role of high-density lipoprotein and lipid soluble antioxidant vitamins in inhibiting low density lipoprotein oxidation. Biochem. J. 294:829-834.
42. McElveen, J., M.I. Mackness, C.M. Colley, T. Peard, S. Warner, and C.H. Walker. 1986. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin. Chem. 32:671-673.
43. Hegele, R.A., J.H. Brunt, and P.W. Connelly. 1995. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler. Thromb. Vasc. Biol. 15:89-95.
44. Serrato, M., and A.J. Marian. 1995. A variant of human paraoxonase/ arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96:3005-3008.
45. La Du, B.N. 1996. Structural and functional diversity of paraoxonases. Nat. Med. 2:1186-1187.
46. Blatter, M.-C., R.W. James, S. Messmer, F. Barja, and D. Pometta. 1993. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45, Identity of K-45 with paraoxonase. Eur. J. Biochem. 211:871-879.
47. Tschopp, J., and L.E. French. 1994. Clusterin: modulation of complement function. Clin. Exp. Immunol. 97 (Suppl. 2):11-14.
48. Rosenberg, M.E., and J. Silkensen. 1995. Clusterin: physiologic and pathophysiologic considerations. Int. J. Biochem. Cell Biol. 27:633-645.
49. Wong, P., J. Pineault, J. Lakins, D. Taillefer, J. Leger, C. Wang, and M. Tenniswood. 1993. Genomic organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis. J. Biol. Chem. 268:5021-5031.
50. French, L.E., A. Wohlwend, A.P. Sappino, J. Tschopp and A. Schifferli. 1994. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J. Clin. Invest. 93:877-884.
51. Aronow, B.J., S.D. Lund, T.L. Brown, J.A. Harmony, and D.P. Witte. 1993. Apolipoprotein J expression at fluid-tissue interfaces: potential role in barrier cytoprotection. Proc. Natl. Acad. Sci. USA. 90:725-729.
52. Hardardottir, I., S.T. Kunitake, A.H. Moser, W.T. Doerrler, J.H. Rapp, C. Grunfeld, and K.R. Feingold. 1994. Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters. J. Clin. Invest. 94:1304-1309.
53. Witte, D.P., B.J. Aronow, M.L. Stauderman, W.D. Stuart, M.A. Clay, R.A. Gruppo, S.H. Jenkins, and J.A. Harmony. 1943. Platelet activation releases megakaryocyte-synthesized apolipoprotein J, a highly abundant protein in atheromatous lesions. Am. J. Pathol. 143:763-773.
54. Jordan-Starck, T.C., S.D. Lund, D.P. Witte, B.J. Aronow, C.A. Ley, W.D. Stuart, D.K. Swertfeger, L.R. Clayton, S.F. Sells, B. Paigen et al. 1994. Mouse apolipoprotein J: characterization of a gene implicated in atherosclerosis. J. Lipid Res. 35:194-210.
55. Jenne, D.E., B. Lowin, M.C. Peitsch, A. Bottcher, G. Schmitz, and J. Tschopp. 1991. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J. Biol. Chem. 266: 11030-11036.
56. Choi-Miura, N.H., Y. Takahashi, Y. Nakano, T. Tobe, and M. Tomita. 1992. Identification of the disulfide bonds in human plasma protein SP-40.40 (apolipoprotein-J). J. Biochem. (Tokyo). 112:557-561.
57. Burkey, B.F., W.D. Stuart, and J.A. Harmony. 1992. Hepatic apolipoprotein J is secreted as a lipoprotein. J. Lipid Res. 33:1517-1526.
58. Navab, M., J.A. Berliner, A.D. Watson, S.Y. Hama, M.C. Territo, A.J. Lusis, D.M. Shih, B.J. Van Lenten, J.S. Frank, L.L. Demer, P.A. Edwards, and A.M. Fogelman. 1996. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff memorial lecture. Arterioscler. Thromb. Vasc. Biol. 16:831-842.